Investors with a lot of money to spend have taken a bearish stance on Recursion Pharmaceuticals (NASDAQ:RXRX). And retail traders should know. We noticed this today when the positions showed up on ...
Recursion Pharmaceuticals' stock had dropped over 50% since February 2024 due to underwhelming clinical results and significant shareholder dilution from a secondary offering and merger. Despite ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback